Feasibility of pancreatectomy following high-dose proton therapy for unresectable pancreatic cancer
Kathryn E Hitchcock, R Charles Nichols, Christopher G Morris, Nancy P Mendenhall, Michael S Rutenberg, Department of Radiation Oncology, University of Florida, Jacksonville, FL 32206, United States
Debashish Bose, Department of Surgical Oncology, UF Health Cancer Center - Orlando Health, Orlando, FL 32806, United States
Steven J Hughes, Department of Surgery, University of Florida, Gainesville, FL 32610, United States
John A Stauffer, Department of Surgery, Mayo Clinic, Jacksonville, FL 32224, United States
Scott A Celinski, Department of Surgery, Baylor University Medical Center at Dallas, Dallas, TX 75246, United States
Elizabeth A Johnson, Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL 32610, United States
Robert A Zaiden, Department of Hematology/Oncology, Baptist Health, Jacksonville, FL 32610, United States
Author contributions: Hitchcock KE, Nichols RC and Rutenberg MS wrote the manuscript; Bose D, Hughes SJ, Stauffer JA, Celinski SA, Johnson EA, Zaiden RA and Mendenhall NP reviewed the manuscript; Morris CG performed statistical analysis; Bose D, Hughes SJ, Stauffer JA, Celinski SA, Johnson EA and Zaiden RA provided patient care.
Institutional review board statement: The University of Florida Health Proton Therapy Institute’s PC-O1 and outcomes-tracking study were approved by an institutional review board at the University of Florida College of Medicine in Jacksonville, FL.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors of this current series have no conflicts of interested to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: R Charles Nichols, MD, Department of Radiation Oncology, University of Florida, 2015 North Jefferson St. Jacksonville, FL 32206, United States. firstname.lastname@example.org
Telephone: +1-904-5881800 Fax: +1-904-5881300
Received: November 17, 2016
Peer-review started: November 23, 2016
First decision: December 29, 2016
Revised: January 28, 2017
Accepted: March 12, 2017
Article in press: March 13, 2017
Published online: April 27, 2017